1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide | 1195966-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
• 英文别名: 1-(3,4-dimethoxyphenyl)-N-[3-(5-methylimidazol-1-yl)propyl]cyclopropane-1-carbothioamide
• CAS: 1195966-14-3
• 化学式: C₁₉H₂₅N₃O₂S
• 分子量: 359.492
• InChiKey: OGHXVAKUSIYDSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  80.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarboxamide 在 劳森试剂 作用下， 以 1,4-二氧六环 为溶剂， 反应 8.0h， 以43.6%的产率得到1-(3,4-dimethoxyphenyl)-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)cyclopropanecarbothioamide
  参考文献：
  名称：

  Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement

  摘要：

  The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of A beta(3,11(pE)-40,42), as these A beta-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of A beta-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of A beta(3,11(pE)-40,42) formation.

  DOI：

  10.1021/jm900969p

文献信息

• COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20180318260A1

  公开（公告）日：2018-11-08

  This invention provides compositions and methods for restoring proper folding and function of Cystic Fibrosis Transmembrane Conductance Regulator mutant with in-flame-deletion of phenylalanine 508 (AF508 CFTR). The invention also provides methods for identifying novel agents capable of restoring proper folding and function of ΔP508 CFTR. The invention additionally provides methods for treating cystic fibrosis.
• [EN] COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DESTINÉS AU TRAITEMENT DE LA FIBROSE KYSTIQUE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2017079547A2

  公开（公告）日：2017-05-11

  This invention provides compositions and methods for restoring proper folding and function of Cystic Fibrosis Transmembrane Conductance Regulator mutant with in-flame-deletion of phenylalanine 508 (AF508 CFTR). The invention also provides methods for identifying novel agents capable of restoring proper folding and function of ΔΡ508 CFTR. The invention additionally provides methods for treating cystic fibrosis.